The retatrutide vs mazdutide comparison represents one of the most consequential questions in next-generation metabolic peptide research: does adding a third receptor (GIP) to the dual GLP-1/glucagon framework produce meaningfully better outcomes? Retatrutide is Eli Lilly’s triple agonist activating GIP, GLP-1, and glucagon receptors — the broadest receptor coverage of any metabolic peptide, with Phase 2 data showing 24.2% average body weight reduction (TRIUMPH-1) and Phase 3 results reaching 28.7% (TRIUMPH-4). Mazdutide is Innovent Biologics’ dual GLP-1/glucagon agonist — the same receptor pair as survodutide but a different molecular design — with Phase 3 data from the DREAM program showing significant weight loss and metabolic improvements in predominantly Chinese populations. Same disease target, different receptor strategies, different development stages, and different patient populations studied — making this comparison essential and practically important for researchers evaluating the next wave of metabolic interventions.

PSPeptides carries both: Retatrutide ($39.99-$139.99) and Mazdutide ($54.99). For the full metabolic peptide landscape, see our weight loss guide, retatrutide guide, and survodutide vs retatrutide vs tirzepatide comparison.

How Do Retatrutide and Mazdutide Work Differently?

Retatrutide — triple GIP/GLP-1/Glucagon agonist: Retatrutide activates three metabolic receptors simultaneously. GLP-1 receptor activation suppresses appetite through hypothalamic satiety signaling, slows gastric emptying, and enhances insulin secretion. GIP receptor activation potentiates insulin response, promotes healthy adipocyte remodeling, modulates brain reward circuits to reduce food-seeking behavior, and may promote brown fat activation. Glucagon receptor activation stimulates hepatic energy expenditure, promotes glycogenolysis, and may directly increase basal metabolic rate — the only receptor in this combination that actively increases caloric output rather than reducing caloric input. The three-receptor approach makes retatrutide the broadest-spectrum metabolic peptide: appetite suppression (GLP-1 + GIP), insulin optimization (GLP-1 + GIP), and energy expenditure enhancement (glucagon). Published TRIUMPH-4 Phase 3 data showed 28.7% body weight reduction — the highest published figure for any metabolic peptide compound.

Mazdutide — dual GLP-1/Glucagon agonist: Mazdutide activates GLP-1 and glucagon receptors without GIP. The GLP-1 component provides appetite suppression and glycemic control. The glucagon component provides hepatic energy expenditure and potential liver fat reduction — the same glucagon-mediated mechanism that retatrutide and survodutide utilize for metabolic rate enhancement. The absence of GIP distinguishes mazdutide from retatrutide — GIP’s contributions to insulin potentiation, adipocyte remodeling, and brain reward modulation are absent from mazdutide’s mechanism. Published Phase 3 DREAM trial data has shown significant weight loss and glycemic improvements, though the magnitude is generally lower than retatrutide’s triple-agonist results.

Retatrutide vs Mazdutide: Complete Comparison

The GIP Question: What Does the Third Receptor Add?

The central and most consequential pharmacological question in the retatrutide vs mazdutide comparison is whether GIP receptor activation meaningfully improves metabolic outcomes beyond what GLP-1 + glucagon alone can achieve. The published data strongly suggests it does — retatrutide’s weight loss (28.7%) exceeds survodutide’s (~19%) and mazdutide’s Phase 3 numbers, and the TRIUMPH head-to-head trial (TRIUMPH-5) comparing retatrutide directly to tirzepatide (dual GIP/GLP-1) is expected to report in late 2026.

GIP’s specific contributions include enhanced insulin secretion beyond what GLP-1 alone produces (GIP is responsible for approximately 60% of the incretin effect after oral glucose), promotion of adipocyte differentiation and healthy fat tissue function (potentially reducing the metabolically dangerous visceral fat that contributes to insulin resistance), and modulation of brain reward circuits through GIP receptors in the hypothalamus and brainstem (contributing to reduced food-seeking behavior and what patients describe as reduced “food noise”). Whether these GIP-specific effects translate to clinically meaningful outcome differences beyond the weight loss numbers requires the ongoing head-to-head trials — but the magnitude of the difference between triple and dual agonist weight loss data is substantial enough to suggest GIP contributes meaningfully.

Liver Fat Reduction: A Critical Differentiator

Both retatrutide and mazdutide have published liver fat data — and this dimension may be where the glucagon receptor activation shared by both compounds provides their most distinctive benefit compared to GLP-1-only or GIP/GLP-1 compounds that lack glucagon activity.

Retatrutide’s TRIUMPH-3 Phase 2 data showed an extraordinary 82% relative reduction in liver fat content — with resolution of metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) in a significant proportion of treated subjects. These liver-specific results are among the most dramatic published for any metabolic peptide and reflect glucagon’s known hepatic effects: glucagon receptor activation stimulates hepatic fatty acid oxidation, reduces de novo lipogenesis, and promotes glycogen breakdown — collectively mobilizing and metabolizing the excess fat stored in hepatocytes that defines steatosis.

Mazdutide’s DREAM-NASH program has also generated liver fat reduction data in Phase 3, consistent with the shared GLP-1/glucagon mechanism. Both compounds benefit from glucagon’s hepatic effects, but retatrutide’s additional GIP receptor activation may provide supplementary liver benefits through GIP-mediated improvements in adipocyte function and insulin sensitivity that reduce the metabolic drivers of hepatic fat accumulation in the first place. For researchers studying the metabolic peptide landscape for liver applications, survodutide (another GLP-1/glucagon dual agonist) also has a dedicated SYNCHRONIZE-NASH trial — see our three-way metabolic comparison.

Population Differences: Western vs East Asian Clinical Data

An important methodological consideration in the retatrutide vs mazdutide comparison is that these compounds have been studied primarily in different populations. Retatrutide’s TRIUMPH program enrolled global populations across the US, Europe, and Asia. Mazdutide’s DREAM program enrolled predominantly Chinese populations. This matters because metabolic disease presentation, body composition, insulin sensitivity, and drug response can differ between Western and East Asian populations.

Published research has documented that East Asian populations develop metabolic complications (type 2 diabetes, cardiovascular risk) at lower BMI thresholds than Western populations — meaning the clinical significance of a given percentage weight loss may differ between populations. Asian populations also tend to have higher visceral-to-subcutaneous fat ratios and different genetic variants affecting incretin receptor signaling. These well-documented population-specific metabolic and genetic factors mean that direct numerical comparison between retatrutide and mazdutide weight loss percentages should be interpreted cautiously — the 28.7% vs mazdutide’s numbers may reflect both genuine pharmacological differences (triple vs dual agonism) and population-level differences in metabolic disease biology and treatment response.

For researchers who want to evaluate both approaches within the same population and testing standards, PSPeptides carries both retatrutide and mazdutide — enabling controlled comparative research designs that eliminate the inter-population confounding present in the published clinical trial datasets.

When to Choose Retatrutide

Maximum weight loss research: Retatrutide’s 28.7% body weight reduction is the highest published number for any metabolic peptide — making it the choice for research seeking maximum adiposity reduction. The triple-receptor breadth provides the most comprehensive metabolic intervention available.

Liver fat reduction: TRIUMPH-3 Phase 2 data showed 82% liver fat reduction — extraordinary for a metabolic peptide and relevant to MASH/NASH research. Published data includes resolution of steatohepatitis in a significant proportion of treated subjects. For liver-focused research, see our retatrutide guide.

Multi-receptor metabolic biology: When the research question involves the interaction between GIP, GLP-1, and glucagon signaling — how three-receptor co-activation produces effects that dual-receptor approaches cannot — retatrutide is the research tool that provides the broadest receptor coverage. See our retatrutide vs tirzepatide comparison.

When to Choose Mazdutide

GLP-1/Glucagon-specific research: When the study question specifically concerns the dual GLP-1/glucagon mechanism without GIP confounding — for example, isolating glucagon’s contribution to energy expenditure in the presence of GLP-1-mediated appetite suppression — mazdutide provides cleaner dual-receptor data than retatrutide’s triple-receptor activation.

Research building on Chinese clinical data: Mazdutide’s DREAM clinical program has generated extensive data in Chinese populations — relevant for researchers studying metabolic peptide effects in East Asian demographics where metabolic disease presentation and body composition may differ from Western populations.

Comparative research designs: Researchers who want to compare dual (GLP-1/glucagon) versus triple (GIP/GLP-1/glucagon) receptor activation can use both PSPeptides compounds — mazdutide and retatrutide — in parallel arms to evaluate whether the addition of GIP produces measurable differences in their specific endpoints.

Side Effect Profiles: Triple vs Dual Agonist Tolerability

Both retatrutide and mazdutide produce the GI side effects typical of all GLP-1-class compounds — nausea, diarrhea, vomiting, and decreased appetite — with frequency and severity generally following the degree of receptor activation. A key question in the triple vs dual comparison is whether the additional GIP receptor activation in retatrutide meaningfully changes the side effect profile compared to dual GLP-1/glucagon agonists like mazdutide.

Published TRIUMPH data shows that retatrutide GI side effects follow a dose-dependent pattern and are generally consistent with other GLP-1 class compounds. The gradual dose escalation protocol used in the TRIUMPH trials was specifically designed to minimize GI events by allowing physiological adaptation. Mazdutide DREAM trial data similarly reports typical GLP-1-class GI events. Without head-to-head data directly comparing retatrutide and mazdutide GI tolerability in the same population, definitive statements about relative tolerability are premature.

The glucagon receptor activation shared by both compounds introduces one additional consideration: glucagon stimulates hepatic glucose output, which theoretically could impair glycemic control. Published data from both TRIUMPH and DREAM programs shows that the concurrent GLP-1 activation (which improves glycemic control) appears to offset glucagon-mediated glucose elevation in most subjects — but monitoring glucose metabolism is relevant in both triple and dual agonist research protocols.

Practical Protocol Considerations

For researchers running comparative retatrutide vs mazdutide protocols, several practical design considerations help ensure meaningful data. Both compounds should be sourced from the same supplier (PSPeptides carries both) to eliminate quality and purity as confounding variables. Both should be reconstituted using the same protocol — bacteriostatic water per our reconstitution guide. Dose escalation schedules should be matched in relative terms (same percentage of maximum dose at each week) rather than absolute dose — since the two compounds have different potencies per microgram. Body composition endpoints should be measured by validated methods (DEXA, CT, or BIA) rather than weight alone, since the compounds may produce different fat-to-lean-mass loss ratios. For the full metabolic comparison landscape, see our three-way metabolic comparison and our weight loss peptide guide.

Reconstitution and Protocols

Both compounds require reconstitution with bacteriostatic water per our reconstitution guide. For dosing calculations, see our dosage calculator. Both are typically administered weekly by subcutaneous injection. Storage at 2-8°C per our storage guide. For side effects common to GLP-1-class compounds, see our side effects guide. For the broader metabolic comparison landscape, see our semaglutide vs retatrutide vs tirzepatide three-way comparison and our CagriSema vs retatrutide comparison.

The TRIUMPH-5 Head-to-Head: What to Expect

Perhaps the most anticipated clinical trial result in metabolic peptide research is TRIUMPH-5 — Eli Lilly’s Phase 3 head-to-head comparison of retatrutide versus tirzepatide in adults with obesity. This is the first controlled trial directly comparing triple agonism (GIP/GLP-1/glucagon via retatrutide) against dual agonism (GIP/GLP-1 via tirzepatide) in the same study population with the same endpoints and the same methodology. The trial began enrolling in November 2024 and results are expected in late 2026.

TRIUMPH-5 will definitively answer the question of whether the addition of glucagon receptor activation to the GIP/GLP-1 framework produces statistically significant superior weight loss — controlling for population, duration, dose escalation, and measurement methodology. If retatrutide produces statistically and clinically significantly greater weight loss than tirzepatide in this head-to-head design, it will validate the triple-agonist hypothesis: that glucagon-mediated energy expenditure adds meaningfully to the appetite suppression provided by GIP and GLP-1. If the difference is modest or non-significant, it will suggest that the additional complexity of triple receptor activation may not justify the pharmacological tradeoff. For researchers following the metabolic peptide landscape, this trial represents the highest-quality evidence that will be available for the retatrutide vs tirzepatide question. See our retatrutide vs tirzepatide comparison for the current evidence and our dosage guide for protocol details.

PSPeptides: The Only Source Carrying Both Compounds

PSPeptides is one of the few research peptide suppliers offering both retatrutide (from $39.99) and mazdutide ($54.99) — enabling researchers to conduct comparative studies using compounds from the same supplier with the same quality standards, 99%+ purity verification, and batch-specific Certificates of Analysis. This eliminates supplier quality as a confounding variable in comparative research designs. Both compounds ship with free shipping, same-day processing, and Afterpay/Klarna payment options. For the complete metabolic peptide catalog that also includes tirzepatide, survodutide, CagriSema, and AOD-9604, visit the PSPeptides shop. For reconstitution guidance, see our reconstitution guide. For dosing, see our dosage calculator guide. Both compounds are administered by weekly subcutaneous injection following gradual dose escalation protocols to minimize GI side effects. Storage at 2-8°C per our storage guide. For researchers who want the broadest metabolic comparison context, our three-way comparison covers semaglutide vs retatrutide vs tirzepatide, our CagriSema comparison covers the GLP-1/amylin approach, and our weight loss peptide guide covers the full metabolic landscape including non-incretin approaches like MOTS-C and 5-Amino-1MQ.

PSPeptides ofrece envío gratuito en todos los pedidos a los 50 estados de EE.UU., Puerto Rico, y todas las direcciones militares APO, FPO, y DPO — sin mínimo de compra requerido. Los pedidos superiores a doscientos dólares califican automáticamente para envío UPS 2nd Day Air gratuito. El procesamiento el mismo día asegura que los pedidos realizados antes del horario de corte diario entran al sistema de correo inmediatamente, minimizando el tiempo de espera entre el pedido y la recepción. Las opciones de pago incluyen todas las tarjetas de crédito principales (Visa, Mastercard, American Express, Discover), Apple Pay, Google Pay, y los servicios de compre ahora pague después Afterpay y Klarna que permiten dividir cualquier compra en cuatro pagos iguales sin interés — recibiendo el pedido inmediatamente mientras distribuye el costo durante las siguientes seis semanas. Todos los productos de PSPeptides incluyen pureza verificada del noventa y nueve por ciento o superior mediante análisis de cromatografía líquida de alta resolución y espectrometría de masas realizados por laboratorios analíticos independientes de terceros, con Certificados de Análisis específicos por lote disponibles para verificación del investigador. La manufactura estadounidense bajo estándares regulados federales proporciona trazabilidad completa de la cadena de suministro y control de calidad consistente que las importaciones de fuentes no reguladas en otros países no pueden igualar. El soporte al cliente está disponible siete días por semana por teléfono al ochocientos ochenta y ocho setecientos dos mil setecientos diecinueve, de nueve de la mañana a diez de la noche hora del este, con personal real contestando llamadas — no sistemas automatizados ni bots de respuesta.

Frequently Asked Questions

What is the difference between retatrutide and mazdutide?

Retatrutide activates three receptors (GIP + GLP-1 + glucagon) — the broadest coverage of any metabolic peptide. Mazdutide activates two (GLP-1 + glucagon, no GIP). Retatrutide has higher published weight loss data (28.7% Phase 3). The key question is whether GIP receptor activation meaningfully improves outcomes beyond dual-receptor approaches.

Which produces more weight loss?

Retatrutide — 28.7% body weight reduction in Phase 3 (TRIUMPH-4), the highest published for any metabolic peptide. Mazdutide has significant Phase 3 weight loss data from the DREAM program but generally lower than retatrutide’s triple-agonist numbers.

Is mazdutide the same as survodutide?

No. Both are dual GLP-1/glucagon agonists, but they are different molecules from different companies (mazdutide from Innovent Biologics, survodutide from Boehringer Ingelheim). Their receptor binding affinities, pharmacokinetic profiles, and clinical programs differ. See our survodutide vs retatrutide vs tirzepatide comparison for the broader landscape.

Does PSPeptides carry both compounds?

Yes. Retatrutide from $39.99 and mazdutide at $54.99 — enabling comparative research designs evaluating dual vs triple receptor activation within the same supplier’s quality and testing standards.

All PSPeptides products are sold exclusively for research and laboratory use.